Biotech Values

[cooldrinkh2o]

<Taxotere does not have to be included in the label. If taxotere extends survival in this group of patients from 12.2 months to 15 months and the current tesmilifene trial extends life from 12.2 months to 30 months, which treatment will oncologist pick.>

I agree it does not need to be in the label. It does for the reps to legally discuss that study with the oncologists, altough there are some exceptions to this.

Also, some oncologists will use it based on the phase III and a phase II with Taxotere. Others want a clean study that does not require inference before they will use it.

The difference in patient populations needs to be addresses here. The Taxotere study you reference is Tax 311. That study looked at patients that received a prior anthracyline. The Tes study was in patients with no prior anthracyline exposure. A different patient group with different outcomes.